Enhancement of Murine Tumor Cell Lysability by Interleukin-2 Activated Killer Cells After Treatment with Mitomycin C

概要

論文の詳細を見る
The cytotoxicity of interleukin-2 activated killer cells with antitumor drug, mitomycin C (MMC) against murine tumor cell lines with acquired drug resis-tance was evaluated in vitro by a 51Cr release cytotoxicity assay. Tumor cell lines, a mouse fibrosarcoma cells (MCA-F) and its individual metastatic lung clones (MCA-F-M1, 2, 3, and 4) have been established in vitro. Furthermore, using a soft agar cloning technique, MMC resistant clones (MCA-F-M2-1, 2, 4, 8, and 10) and sensitive clones (MCA-F-M1-3, MCA-F-M3-8, 9, MCA-F-M4-9, and 10) were established and their lysability was examined with or without MMC against lymphokine-activated killer (LAK) cells, demonstrating that LAK cells showed high % cytotoxicity against 2 resistant clones (MCA-F-M2-1 and 8) by the 7 day-exposure of 1.0 pg/ml MMC concentration in culture but with a low % cytotoxicity in the case of only 3 day-MMC exposure. The other resis-tant clones showed high % cytotoxicity at 3 day-MMC exposure. On the other hand, all the sensitive clones showed high % cytotoxicity against LAK cells with the only 1 day-exposure of MMC. Thus, the combination of LAK cells and MMC treatment had a synergistic effect on MMC resistant clones as well as sensitive clones and these results suggested that the lysability of MMC resistant clones might be due to the altered susceptibility to LAK cells by use of MMC time-dependently.
札幌医科大学の論文
1992-00-00